ADMA Biologics reports Thursday with a familiar tension: a stock that has rallied 11.5% over the past month is now pulling back into the number, down 6% on the week to $10.25, while short interest has quietly rebuilt after reaching a multi-week low just days ago.
The short side of the ledger is the most interesting feature right now. At 9.8% of the free float, short interest is running near the top of its six-week range, having dipped to a trough around 9.0% in late April before climbing back with an 8.3% week-on-week rise in shares short. That's a meaningful re-engagement by bears — not a new extreme, but a clear reversal from the brief period of covering. Borrow conditions offer no constraint on that activity: cost to borrow is a negligible 0.46%, down slightly on the week, and availability in the lending pool remains generous. With utilization well under 10% of available inventory and far from its 52-week peak of 14.9%, new shorts face no friction entering ahead of the print.
Options positioning has grown more defensive in parallel, though not dramatically so. The put/call ratio has crept to 0.39, sitting roughly 1.6 standard deviations above its 20-day average of 0.33 — a mild elevation rather than an alarm. The year-to-date range runs from 0.23 to 0.81, so the current reading is closer to the call-heavy end of the spectrum than a true fear spike, suggesting that while some investors are buying downside protection, the majority of options flow remains tilted toward calls. The short score of 49.3 is broadly neutral — roughly the 37th percentile of its sector — consistent with a stock that is meaningfully shorted but not in squeeze territory.
The Street backdrop is mixed and worth treating carefully given timing. Canaccord Genuity initiated with a Buy and a $21 target in late April — the most recent action and a welcome addition to the bull camp. Mizuho maintained its Outperform rating earlier in April but trimmed its target from $30 to $24, a signal that the firm still likes the story but has moderated near-term expectations. Cantor Fitzgerald's downgrade to Neutral in late March added a meaningful bear voice. Three analysts currently carry a Buy-equivalent, with the consensus mean target at $20.67 — roughly double where the stock now trades at $10.25. That gap implies the Street sees significant upside, but notable target cuts and the Cantor downgrade show sentiment has cooled from its peak. Valuation multiples remain modest: the trailing P/E is around 9.7x, EV/EBITDA near 6.9x and edging down over the past month, suggesting the market is not paying a premium for growth here. Forward EPS estimates are tracking 84th percentile year-on-year increases within the universe — the fundamental growth story is intact even as the stock has de-rated.
On the ownership side, Sachem Head Capital Management and Capital Research both made notable builds in recent quarters, adding 2.4 million and 3.4 million shares respectively as of their latest filings. The CEO, Adam Grossman, sold shares in March at prices between $15.39 and $15.16 — well above current levels — while VC board-representative Aisling Capital made modest open-market purchases around the same prices. The net insider picture over 90 days is a small positive in share terms, but the executive sales at prices 50% above the current level are a data point worth noting in context.
The prior two earnings prints showed limited drama: a flat-to-slight-negative day-one move and then a five-day drift of minus 4.5% after March's report, and a 2% down day recovering to a 6.6% five-day gain after February's release. Neither event produced a sharp directional move. With short interest back near the top of its recent range and options a degree more defensive than usual, Thursday's Q1 print is set up as a test of whether the recovery from April's lows has fundamental backing — or whether the shorts who rebuilt this week were positioned correctly.
See the live data behind this article on ORTEX.
Open ADMA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
